Get the Stockscreener App
49.55
7.32%
3.38
After Hours:
50.50
0.95
+1.92%
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals completes $134.8M stock offering By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals completes $134.8M stock offering - Investing.com
Tarsus prices $125M stock offering - MSN
Tarsus Pharma dips after upsized $125 mln stock offering - TradingView
Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering -March 13, 2025 at 03:44 am EDT - Marketscreener.com
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewswire
Tarsus Pharmaceuticals launches $100 million stock offering - Investing.com Australia
Tarsus Secures Massive $125M Capital Raise as Investors Rush Into Upsized Offering - StockTitan
Tarsus Announces Pricing Of Upsized $125 Million Public Offering -March 12, 2025 at 09:50 pm EDT - Marketscreener.com
Tarsus Pharmaceuticals dips on planned $100 million equity raise - TradingView
Tarsus Pharmaceuticals launches $100 million stock offering By Investing.com - Investing.com Canada
Tarsus Announces Proposed $100.0 Million Public Offering - GlobeNewswire
Tarsus Pharmaceuticals’ SWOT analysis: specialty pharma stock faces growth hurdles By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals’ SWOT analysis: specialty pharma stock faces growth hurdles - Investing.com
Tarsus Pharma: Strong Execution In Xdemvy Commercialization (NASDAQ:TARS) - Seeking Alpha
Oppenheimer & Co. Inc. Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 5.8% Following Analyst Upgrade - Defense World
Contrasting PharmaCyte Biotech (OTCMKTS:PMCBD) & Tarsus Pharmaceuticals (NASDAQ:TARS) - Defense World
Tarsus to Participate in Upcoming Investor Conference - GlobeNewswire
Tarsus Pharmaceuticals Inc (TARS) to Participate in Barclays Global Healthcare Conference - GuruFocus.com
Healthcare Spotlight: Tarsus Takes Center Stage at Major Barclays Conference - StockTitan
Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies - TipRanks
Tarsus Pharmaceuticals (NASDAQ:TARS) & Aura Biosciences (NASDAQ:AURA) Critical Survey - Defense World
William Blair Has Negative Forecast for TARS Q1 Earnings - MarketBeat
Rhumbline Advisers Purchases 1,019 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Trend Tracker for (TARS) - Stock Traders Daily
New York State Common Retirement Fund Reduces Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Lifesci Capital Weighs in on TARS Q1 Earnings - MarketBeat
Tarsus Pharmaceuticals’ (TARS) Buy Rating Reiterated at HC Wainwright - Defense World
Barclays Cuts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $60.00 - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Quarterly Earnings Results - MarketBeat
Q1 Earnings Forecast for TARS Issued By Lifesci Capital - Defense World
William Blair Issues Pessimistic Outlook for TARS Earnings - Defense World
Brokers Issue Forecasts for TARS Q1 Earnings - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Given Buy Rating at HC Wainwright - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Barclays Has Lowered Expectations for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price - MarketBeat
Y Intercept Hong Kong Ltd Acquires New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Decoding Tarsus Pharmaceuticals Inc (TARS): A Strategic SWOT Ins - GuruFocus.com
Q1 Earnings Forecast for TARS Issued By William Blair - MarketBeat
What is HC Wainwright’s Estimate for TARS Q4 Earnings? - Defense World
Q1 Earnings Estimate for TARS Issued By William Blair - Defense World
Brokers Issue Forecasts for TARS FY2025 Earnings - Defense World
Tarsus Pharmaceuticals’ Earnings Call Highlights Success and Challenges - TipRanks
What is Lifesci Capital's Estimate for TARS FY2025 Earnings? - MarketBeat
Tarsus Pharmaceuticals: Undervalued Growth Potential and Acquisition Appeal Reinforce Buy Rating - TipRanks
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2024 Earnings Call Transcript - MSN
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):